Friday, June 06, 2008

Deadly Hit and Run, InHuman bystanders of Hartford?

It is absolutely terrifying and disturbing to see this hit and run accident in Hartford, the cars keep rolling, people seems to walk around as though there is nothing to be concerned about?, despite this hartford man knocked out by a deadly bastard who took off the road without any remorse or concern to the human he had hit on the middle of the road?.



http://www.courant.com/

Wednesday, April 09, 2008

April Cure News!


April 2008




Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org TELL A FRIEND

Events Column
4/11 8:00 am - 6:30 pm. Healthcare 2008 at the Yale School of Management. "Whose Healthcare is it Anyway? Understanding the Patient as a Consumer." Omni Hotel, New Haven, CT. more
4/16 3:30 pm - 6:00 pm. CURE and Yale OCR Present: The Next Big Idea - Creating a New Venture. A Special BioHaven Entrepreneurship Panel with Roger Longman of Windhover Publications. Reception and networking to follow. Anlyan Center, Congress Avenue, New Haven, CT. more
4/19 8:00 am. Final round presentations begin re Y50K annual business plan competition. more
4/23 3:00 pm - 6:00 pm. CURE and Yale OCR Present: Vidus Ocular. A BioHaven Entrepreneurship Seminar. Anlyan Center, Congress Avenue, New Haven, CT. Reception and networking to follow. more
4/29-30 Connecticut Venture Group. Crossroads Venture Fair. Marriott Hotel, Stamford. more

New Haven News & Activities!!



Yale-New Haven Hospital is pleased to present its latest annual report, which tells the stories of six patients who put their lives in the hands of the staff at Yale-New Haven Hospital.

One was an auto accident victim, another was a high-risk maternity patient; one had cancer; one needed a liver transplant and two had serious cardiac problems. Some of these patients might not have survived had they gone to another hospital ? and all of these patients ended up grateful that they put their trust in the care and expertise at Yale-New Haven Hospital.

The report also includes: the 2007 financial statement and comparative statistics; a year-end report from the chief executive officers; a list of the hospital?s management and medical staffs; and the names of donors and companies who provided financial support during the past year.

Go to the annual report now.

Click here for YNHH home page.

News this month

Bicycle-related injuries result in more emergency department visits than from any other recreational sport

smith

Preventing
bicycle-related injuries

Each year in the United States, about 500,000 children are injured and 250 die in bicycling accidents.

Head injuries are one of the most serious ways that children get hurt while riding their bicycles. Children should always wear helmets, and parents should model this protective measure as well. The American Medical Association calls helmets the single most cost-effective safety device ever made.

Children will learn to ride a bike when they are ready. It is important to never push a child to ride a bike. When children are very young, a smart way to teach them bicycle safety is by example. Today?s child safety carriers and other options give parents the opportunity to spend quality time with their children while introducing them to the joys of riding.

'The American Medical Association calls helmets the single most cost-effective safety device ever made.'

Because children mature both physically and emotionally at differing rates, there?s no magic age to introduce a child to a "big kid?s" bike. But in general, most 4- or 5-year-olds have acquired the motor skills needed to mount and balance a bicycle. When buying a bike, make sure it fits your child. Do not buy a bike that your child will have to grow into. Oversized bikes are especially dangerous.

For full protection, a helmet should sit low on the head ? about an inch above the eyebrows ? and the chinstrap should be snug. Wearing a helmet far back on the head or very loosely will not protect the head. Also, be aware that Connecticut state law requires all children age 16 and under to wear a bicycle helmet on public roads.

An infant who cannot hold up his head when wearing a small helmet should not ride on a bike. Young children who can sit well unsupported and whose necks can support wearing bike helmets should ride in rear-mounted seat carriers. Children with special needs may require adapted seating to safely secure them on a bike or carrier.

When children and teenagers are injured in bike accidents, the most commonly affected anatomic areas are the upper and lower extremities, head, neck and trunk. According to a recent article in American Family Physician, the injuries may range in severity from bruises, contusions and "road rash" to full multi-system trauma.

Although less common, bike accidents occurring from vehicular trauma tend to be worse than off-road biking injuries, and they have a higher fatality rate. Chronic overuse injuries in dedicated or competitive bike riders may also present in the form of saddle sores or neuropathy of the wrist.

At Yale-New Haven Children?s Hospital (YNHCH), the entire range of pediatric specialists are available to care for children and teenagers injured in bike accidents; from pediatric neurosurgery and maxillofacial surgeons to pediatric general and orthopedic surgeons.

Comprehensive care of the pediatric trauma patient injured in a bicycle accident begins in the YNHCH emergency department, the only designated pediatric Level 1 trauma service in Connecticut. For less acute physical problems, outpatient care for children with bike injuries is also available in the orthopedic department of the Yale School of Medicine at the Yale Physicians Building.


Dr. Smith is chief of pediatric orthopedics at Yale-New Haven Children?s Hospital and associate professor of orthopedics at Yale School of Medicine.

Bicycles offer children a sense of accomplishment and, for older children and adolescents, a feeling of freedom and mobility. But there are risk factors in bike riding and when a child takes a tumble, injuries as minor as scraped knees and as severe as death can occur.

Wearing a properly fitted and safety-approved bicycle helmet can reduce head injuries by up to 85 percent.

Children and adolescents age 20 years and younger comprise more than half of the estimated 85 million bicycle riders in the U.S. and account for more emergency department visits than from any other recreational sport.

A new study conducted by researchers at the Center for Injury Research and Policy at Nationwide Children?s Hospital estimates that approximately 10,700 children are hospitalized annually for bicycle-related injuries in the U.S. The average length of stay is three days.

The study, published in the October 2007 issue of Injury Prevention, concludes that bicycle-related injuries among children and adolescents in the U.S. may be a more significant public health concern then previously estimated. The study also estimates that bicycle-related injuries among children and adolescents result in nearly $200 million in hospital inpatient charges annually.

"Bicycles are associated with more childhood injuries than any other consumer product except automobiles," said Gary Smith, MD, DRPH, director of the Center for Injury Research and Policy and one of the study authors. " The high rate of hospitalization and the use of healthcare resources identified in our study supports the need for increased attention to bicycle-related injuries." The study analyzed patient and injury characteristics associated with bicycle injuries using a nationally representative sample. Among the significant findings: motor vehicles were involved in approximately 30 percent of bicycle-related hospitalizations, and the association with motor vehicles increased among older children.

In addition, one-third of children hospitalized for a bicycle-related injury were diagnosed with traumatic brain injury, a statistic that is significant for its correlation to the number of injuries that may be preventable through the use of bicycle helmets.

"Studies have shown that wearing a properly fitted and safety-approved bicycle helmet can reduce head injuries by up to 85 percent," said John T. Gill, MD, spokesman for the American Academy of Orthopedic Surgeons. " However, only about half of cyclists bother to put on a helmet before they ride."

According to Safe Kids Worldwide, a global network of organizations whose mission is to prevent accidental childhood injuries, in children age 14 and under, more than 80 percent of bicycle-related fatalities are associated with the bicyclist?s behavior.

For example, riding into a street without stopping, turning left or swerving into traffic that is coming from behind, running a stop sign, and riding against the flow of traffic all contribute to injuries. Nearly 60 percent of all childhood bicycle-related deaths occur on minor roads.

"The findings from our study can be used to promote targeted prevention strategies to lessen the severity of injury and the number of deaths resulting from pediatric bicycle-related injuries," said Dr. Smith.

.



Related links and online resources


For more information on this topic:

Other pediatric resources


Previous issues of HealthLINK ? Pediatrics

  • July 2007 - Obese children more than twice as likely to have diabetes
  • February 2007 - Sleep problems linked to lower IQ scores and learning impairments
  • December 2006 - Children who need emergency care have better outcomes at pediatric trauma centers
  • July 2006 - Study shows sports drinks can cause tooth decay
  • May 2006 - Warning urged for Attention Deficit Hyperactivity drugs
  • December 2005 - Revised recommendations on reducing Sudden Infant Death Syndrome
  • December 2005 - Revised recommendations on reducing Sudden Infant Death Syndrome
  • September 2005 - New meningococcal vaccine recommended
  • August 2005 - Increase in adult-type injuries among children and adolescents
  • March 2005 - Food allergen labeling
  • February 2004 - Throw out syrup of ipecac
  • August 2003 - Preemies show gains over time
  • April 2003 - Potty training study offers answers
  • February 2003 - Can booster seats save lives?
  • July 2002 - Eye drops as effective as patching?
  • May 2002 - Scooter, skateboard injuries rise with popularity
  • April 2002 - Looking at asthma in preschoolers
  • November 2001 - The cost of getting the flu
  • Archive






















Thursday, February 28, 2008


idea
A look at the future of therapeutics.
Insight from leading industry observers on new trends in business formation.
Roger Longman (moderator)
Leading expert in biopharmaceutical deal-making
Managing Partner, Windhover Information, Inc.
William Burkoth
Board observer for five Pfizer-supported new ventures
Senior Manager Venture Capital, Pfizer Venture Investments, Pfizer Inc.
Richard Flavell, Ph.D., FRS
Founding scientist, Vaxinnate
Yale Professor and Chairman of Immunobiology
Yale Professor of Molecular, Cellular & Developmental Biology Investigator, Howard Hughes Medical Institute
Haifan Lin, Ph.D.
Internationally recognized stem cell researcher
Yale Professor and Director of the Yale University Stem Cell Center
David Scheer
Venture capitalist and expert in life sciences company formation, President, Scheer & Company, Inc.
DATE
April 16, 2008
4:30 pm Registration & Refreshments
5:00 pm Seminar
6:45 pm Networking, Heavy Hors
D'oeuvres & Wine Bar
LOCATION
The Anlyan Center Auditorium
Yale University Medical School
300 Cedar Street, New Haven, CT
Directions & Parking
RSVP REQUIRED
www.regonline.com/biohaven


Published by Connecticut United for Research Excellence
Copyright © 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
TELL A FRIEND
Powered by IMN
This email was sent to:drmuni .com
From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA

(REMOVE) - to be excluded from this list and/or future mailings.
(CHANGE FORMAT) - receive future messages in plain text format.
(REPORT ABUSE) and remove me from the list.

Wednesday, February 06, 2008

New Haven-CT, BioScience Community activity!




























Friday, January 11, 2008



















.



Tuesday, February 12, 2008
Rib-X Pharmaceuticals, Inc.





Followed by networking, refreshments & wine bar



Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent.


Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics.


Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome.


The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million.

Speakers











Susan Froshauer, Ph.D.

President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc.

Erin Duffy, Ph.D.


Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc.


Tuesday, February 12, 2008
3:30 P.M. Registration
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar


Location
The Anlyan Center auditorium, Yale Medical School.


Directions & Parking:
http://info.med.yale.edu/maps/cab.html


RSVP
Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209.

Mark Your Calendar
The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here.


Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.














Also sponsored by Elm Street Ventures.



Presented by CURE and the Yale Office of Cooperative Research.










Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society.























Published by Connecticut United for Research Excellence
Copyright © 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
TELL A FRIEND




Powered by IMN
This email was sent to: edu@drmuni.com
From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA

(REMOVE) - to be excluded from this list and/or future mailings.
(CHANGE FORMAT) - receive future messages in plain text format.
(REPORT ABUSE) and remove me from the list.



















































Friday, January 11, 2008





































.




Tuesday, February 12, 2008
Rib-X Pharmaceuticals, Inc.







Followed by networking, refreshments & wine bar





Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent.



Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics.



Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome.



The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million.

Speakers





















Susan Froshauer, Ph.D.

President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc.


Erin Duffy, Ph.D.



Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc.



Tuesday, February 12, 2008
3:30 P.M. Registration
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar



Location
The Anlyan Center auditorium, Yale Medical School.



Directions & Parking:
http://info.med.yale.edu/maps/cab.html



RSVP
Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209.

Mark Your Calendar
The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here.



Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.



























Also sponsored by Elm Street Ventures.




Presented by CURE and the Yale Office of Cooperative Research.



















Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society.





































Published by Connecticut United for Research Excellence
Copyright © 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
TELL A FRIEND








Powered by IMN
From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA


CURE Bio News & New Haven-CT

Wednesday, February 6, 2008
--------------------------------------------------------------------------------
Long Wharf Theater Outing Draws Bioscience Community Together

Event chair David Scheer of Scheer and Company and sponsor Jay Brotman of Svigals+Partners.
Connecticut's bioscience community joined local arts leaders January 30 under the auspices of CURE for cocktails, dinner, and a performance at New Haven's Long Wharf Theater of "Let Me Down Easy.

" The new one-woman show about the human body features the acclaimed performer Anna Deveare Smith portraying Yale School of Medicine faculty and others interviewed over several years for her project.

Prior to the show, plenty of networking and dealmaking took place during the Italian buffet supper at Leon's -- the former Rusty Scupper on Long Wharf Drive.

Click the link for full report!
--------------------------------------------------------------------------------
Published by Connecticut United for Research Excellence
Copyright © 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org TELL A FRIEND by IM

What is Happening in New Haven-CT?

Well, Obama won the CT primary, good job CT. Here are some top of the line website in Connecticut which supports Obama and sites with latest news about Obama!


http://ctobama.ning.com/
http://www.obamact.blogspot.com/
&
http://www.ctnewsjunkie.com/
http://www.blognetnews.com/connecticut/


Wednesday, January 16, 2008

"Let Me Down Easy" By Anna Deveare Smith


CURE News


Event Chairmen

Paul Pescatello, President, CURE

David Scheer, President, Scheer & Co

SIGN UP EARLY



Supper and Arts Outing at Long Wharf
for Connecticut's pharma and biotech communities

Wednesday, January 30, 2008
Supper: 5 - 6:45 pm
Theater Curtain: 7 pm

"Let Me Down Easy"
by Tony-award winning playwright and actress
Anna Deveare Smith
Winner of a MacArthur Foundation "genius" fellowship and hailed by Newsweek as "the most exciting individual in American theatre"


This one-woman show about the resilience and fragility of the human body debuted at Yale Medical School where Smith was a visiting professor.




at New Haven's nationally known
Long Wharf Theatre



This is an exciting opportunity to see a play before it heads for New York City.

Bring your spouse.

Share this with colleagues and friends.



Before the show, join us for supper at Leon's
(formerly the Rusty Scupper)

Hear about the play from the producers.
Learn about another New Haven arts jewel, The New Haven Symphony.

Seats are limited. They will be distributed first come, first served. SIGN UP EARLY

Click here for directions to the theater
Click here for directions to the restaurant

Cost for employees of CURE members and their guests (per person):
$45 Theater only. $68 Theater and Dinner

Cost for non members (per person):
$50 Theater only. $110 per person.
Click here to find out if your company is a CURE member

All profits go to DEVELOPING WORLD CURES.
This new New Haven non-profit is dedicated to developing medicines, assays and devices to treat diseases prevelant in the developing world for which existing treatments are not effective or suitable.


CURE & YALE University: Yale BioHaven Enterprenurship





Tuesday, February 12, 2008
Rib-X Pharmaceuticals, Inc.



Followed by networking, refreshments & wine bar

Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent.

Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics.

Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome.

The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million.

Speakers

Susan Froshauer, Ph.D.

President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc.

Erin Duffy, Ph.D.

Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc.

Tuesday, February 12, 2008
3:30 P.M. Registration
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar

Location
The Anlyan Center auditorium, Yale Medical School.

Directions & Parking:
http://info.med.yale.edu/maps/cab.html

RSVP
Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209.

Mark Your Calendar
The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here.

Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.

Also sponsored by Elm Street Ventures.


Presented by CURE and the Yale Office of Cooperative Research.


Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society.




Published by Connecticut United for Research Excellence
Copyright © 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
TELL A FRIEND
Powered by IMN
this e-mail was sent to drmuni
From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA


NewHavener's do say "Our City of New Haven does sleep!!?". New Haven is a constantly growing and quite active city of mixed cultures. The location of green in the midst of downtown, restaurants, beautiful church buildings, sky scrappers and the breathtakingly beautiful Yale buildings provide the special charm to the city of New Haven, in fact, Yale dignifies and signifies the city of New Haven, formed during 1666, one of the oldest city and county, she has 30towns under her county belly.